Quantitative Determination of 50% Hemolysis Rate (CH50): Principles, Methods, and Applications

The quantitative determination of the 50% hemolysis rate, commonly known as the CH50 assay, is a cornerstone immunological technique for measuring total complement activity in serum and other biological samples. By determining the dilution of a sample that lyses exactly 50% of a standardized suspension of antibody-sensitized erythrocytes, this method delivers a sensitive and reproducible index of classical complement pathway function. This article explains the analytical principle, sample requirements, testing methodologies, calculation basis, quality controls, and practical applications of 50% hemolysis rate measurement in clinical diagnostics and biomedical research.

Technical Overview

The 50% hemolysis rate measurement, historically designated CH50 (50% Complement Hemolytic activity), quantifies the functional capacity of the complete classical complement cascade in a test sample. When sheep erythrocytes are coated with specific antibodies (forming so-called EA cells, or sensitized erythrocytes), exposure to a complement source activates the classical pathway, culminating in assembly of the membrane attack complex (C5b–C9) on the cell membrane. The resulting osmotic lysis releases hemoglobin into the surrounding medium, providing a directly measurable optical signal.

The fraction of cells lysed does not increase linearly with complement concentration. Instead, it follows a characteristic sigmoidal dose–response curve described by the von Krogh equation. Because the slope of this curve is steepest at the 50% lysis point, the CH50 endpoint offers maximal analytical sensitivity to small changes in complement activity. One CH50 unit is defined as the quantity of complement required to lyse 50% of a defined number of sensitized erythrocytes under standardized conditions, and results are typically reported as units per milliliter (U/mL) of serum.

Proper execution of the assay depends on tightly controlled variables, including erythrocyte concentration and standardization, antibody sensitization conditions, incubation temperature (typically 37 °C), reaction time, and the ionic composition of the veronal-buffered saline diluent, which must contain calcium and magnesium ions for classical pathway activation. Since complement is heat-labile and degrades rapidly ex vivo, pre-analytical handling is as critical to accuracy as the analytical procedure itself.

Testing Samples

Human Serum

Freshly collected human serum is the principal sample type for clinical CH50 determination. Blood should be allowed to clot at ambient temperature for a limited time (usually no more than 30–60 minutes), separated promptly, and tested the same day or stored frozen at −70 °C or below to preserve complement integrity. Repeated freeze–thaw cycles must be avoided because they progressively inactivate complement components.

Animal Serum

Serum from laboratory animals such as mice, rats, rabbits, and guinea pigs is analyzed in preclinical pharmacology and toxicology studies, particularly when evaluating complement-modulating therapeutics or species-specific complement activation profiles.

Plasma and Anticoagulated Blood

Plasma is generally unsuitable for classical CH50 testing unless the anticoagulant is compatible with complement function. EDTA chelates the divalent calcium and magnesium ions essential for C1 and C3 convertase activity, while heparin and citrate may also interfere; the choice of matrix must therefore be justified and validated.

Biological Products and Medical Device Extracts

Test articles such as complement-containing reagents, blood-contacting biomaterial extracts, and dialysis or extracorporeal circuit components can be evaluated for their effect on, or consumption of, complement activity in accordance with hemocompatibility assessment concepts outlined in ISO 10993-4.

Testing Items

A comprehensive 50% hemolysis testing program typically encompasses the following measurable parameters:

• Total classical pathway complement activity (CH50, U/mL)
• Alternative pathway activity (AH50) using rabbit erythrocytes in magnesium-only buffer
• Percent hemolysis at each serial dilution, used to construct the dose–response curve
• Individual complement component functional activity (C1–C9) when a pathway-level deficiency is detected
• Hemoglobin release quantification by absorbance measurement at approximately 541 nm or 530 nm
• Hemolysis rate of blood-contacting materials calculated from released hemoglobin relative to positive and negative controls

Testing Methods

Traditional Tube Dilution Visual Endpoint Method

Serial two-fold dilutions of the test serum are prepared in veronal-buffered saline containing calcium and magnesium. A constant volume of standardized sensitized sheep erythrocytes is added to each tube, and the mixtures are incubated at 37 °C for a fixed period, typically 30 to 60 minutes. After centrifugation, the degree of hemolysis in each supernatant is compared visually or photometrically against a 50% hemolysis reference standard. The CH50 value is expressed as the reciprocal of the highest dilution producing 50% lysis.

Spectrophotometric Quantification with von Krogh Transformation

For metrologically rigorous quantification, the hemoglobin released in each reaction tube is measured spectrophotometrically. Percent lysis is calculated as the absorbance of the sample divided by the absorbance of a totally lysed (water or ammonium chloride lysed) erythrocyte control, after blank subtraction. The data are then linearized using the von Krogh equation, in which the logarithm of the ratio of percent lysis to percent non-lysis is plotted against the logarithm of serum concentration. The dilution corresponding to exactly 50% hemolysis is read from this linear plot, yielding the CH50 value with improved precision compared with visual endpoints.

Microplate and Automated Kinetic Methods

Adaptation of the assay to 96-well microplates with automated absorbance readers enables higher throughput, reduced reagent consumption, and objective data capture. Kinetic variants monitor the rate of hemoglobin release continuously, allowing endpoint determination before secondary interference occurs.

Alternative Complement Measurement Platforms

These platforms improve standardization and are suitable for laboratories processing large sample volumes, although functional hemolytic assays remain the reference approach for confirming total pathway competence.

Quality Control Measures

Each analytical run should include a certified or internally calibrated reference serum with assigned CH50 activity, a negative control (heat-inactivated serum), a positive total-lysis control, and a reagent blank. Erythrocyte suspensions must be standardized photometrically, sensitization must be performed with a defined optimal dilution of hemolysin, and incubation conditions must be strictly timed. Accredited third-party laboratories commonly participate in inter-laboratory proficiency programs to demonstrate measurement comparability and metrological traceability.

Applications

• Clinical immunology: screening for classical complement pathway deficiencies associated with recurrent infections, autoimmune disease, and hereditary angioedema
• Disease activity monitoring: CH50 is frequently elevated in acute-phase inflammatory states and depressed in systemic lupus erythematosus, immune complex glomerulonephritis, and active autoimmune hemolysis
• Drug development: pharmacodynamic monitoring of complement-inhibiting biologics and dose-finding studies for complement-targeted therapeutics
• Vaccine and adjuvant research: assessment of complement-activating properties of formulations
• Biomaterial hemocompatibility: evaluation of complement activation and hemolysis induced by blood-contacting medical devices in line with ISO 10993-4 concepts and related national standards such as GB/T 16886.4
• Transfusion medicine and blood product quality control, including evaluation of complement preservation in stored serum and plasma derivatives

FAQ

Why is 50% hemolysis used as the endpoint instead of complete lysis?

The complement titration curve is sigmoidal, and its slope is steepest at the midpoint. At 50% lysis, a small change in complement activity produces the largest detectable change in hemolysis, making this endpoint the most sensitive and statistically robust point for quantification. Near total lysis, the curve flattens and becomes insensitive to activity variation.

What is the typical reference range for CH50?

Reference intervals vary with methodology, reagent standardization, and population, but serum CH50 values commonly fall in the approximate range of 26–60 U/mL for adults. Each laboratory must establish and verify its own reference range applicable to the specific assay conditions employed.

What causes falsely low or falsely high CH50 results?

Falsely low values most often result from pre-analytical complement degradation caused by delayed processing, inadequate cold storage, or freeze–thaw cycles. Falsely elevated or reduced values may also arise from improperly standardized erythrocytes, incorrect hemolysin sensitization, contamination with chelating agents, or hemolyzed or lipemic samples that interfere with absorbance readings.

How do CH50 and AH50 assays differ?

CH50 measures classical pathway function using antibody-sensitized sheep erythrocytes and requires both calcium and magnesium ions, whereas AH50 measures alternative pathway function using unsensitized rabbit erythrocytes in buffer containing magnesium only. Running both assays in parallel allows localization of a deficiency to a specific pathway or shared terminal component.

Can the assay be applied to medical device evaluation?

Yes. Quantitative hemolysis measurement principles underpin the hemolysis test used in hemocompatibility evaluation of blood-contacting devices, in which the hemolysis rate of material extracts or direct-contact samples is calculated from released hemoglobin and compared against positive and negative controls, consistent with the framework of ISO 10993-4 and equivalent national standards.